Apoptosis

, Volume 14, Issue 4, pp 607–623

Is TRAIL the holy grail of cancer therapy?

  • Thomas Newsom-Davis
  • Silvia Prieske
  • Henning Walczak
Cell Death and Disease

DOI: 10.1007/s10495-009-0321-2

Cite this article as:
Newsom-Davis, T., Prieske, S. & Walczak, H. Apoptosis (2009) 14: 607. doi:10.1007/s10495-009-0321-2

Abstract

Inducing apoptosis has become an important approach in the development of new anti-cancer treatments. Tumour necrosis factor apoptosis inducing ligand (TRAIL) based therapies have emerged as one of the most promising examples of this as they selectively induce apoptosis in tumour cells. However, many primary tumours are inherently resistant to TRAIL-mediated apoptosis and require additional sensitisation. Here we review apoptotic and non-apoptotic TRAIL-signalling, and the therapeutic effects of TRAIL-based treatments both as monotherapy and in combination with sensitising agents.

Keywords

TRAIL Apoptosis Cancer therapy TRAIL resistance 

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Thomas Newsom-Davis
    • 1
  • Silvia Prieske
    • 1
  • Henning Walczak
    • 1
  1. 1.Tumour Immunology Unit, Department of ImmunologyImperial College LondonLondonUK

Personalised recommendations